Naltrexone and Buspirone Contraindications and Alternatives

Critical Contraindications Present

The American College of Cardiology and other guideline societies recommend that naltrexone-bupropion combination should not be used in patients with active suicidal ideation due to increased risk of suicidal thoughts and behavior, particularly in patients under 24 years with depression, requiring close monitoring especially during initial treatment months 1
The patient's current high dose of buspirone (300mg) suggests inadequate symptom control with current regimen, and depression, PTSD, and anxiety must be stabilized before considering weight management pharmacotherapy, as recommended by the American Psychiatric Association 1, 2

The American Heart Association recommends that naltrexone-bupropion causes blood pressure and heart rate elevations, requiring baseline assessment and periodic monitoring especially in first 12 weeks, and uncontrolled hypertension is an absolute contraindication 1, 2
The combination of naltrexone-bupropion with other medications such as SSRIs can lower seizure threshold, requiring strict adherence to maximum dosing guidelines, as recommended by the National Institute of Neurological Disorders and Stroke 1

The American College of Cardiology recommends focusing on optimizing current antidepressant regimen before considering weight management pharmacotherapy, and addressing suicidal ideation with appropriate psychiatric intervention and close monitoring 1, 2
Intensive behavioral interventions including diet and exercise should be the primary approach for weight loss, as recommended by the Academy of Nutrition and Dietetics, and modest weight loss (even 5kg) through lifestyle modification can improve glucose metabolism, lipid levels, and blood pressure 3
Defer pharmacological weight management until psychiatric stability is achieved and suicidal ideation has resolved, as recommended by the American Psychiatric Association 2

The American Medical Association recommends that psychiatric stabilization should be prioritized over weight management in a patient with active suicidal ideation, and the risk-benefit ratio is unacceptable given this patient's current psychiatric instability and the modest efficacy of naltrexone-bupropion for weight loss 1, 2